Everything below concerns circadian rhythm. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-09. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Dorothy Mary Crowfoot Hodgkin (née Crowfoot; 12 May 1910 – 29 July 1994) was an English chemist who advanced the technique of X-ray crystallography to determine the structure of biomolecules, which became essential for structural biology. She received the 1964 Nobel Prize in Chemistry, and is the only British woman scientist to have been awarded a Nobel Prize. Among her most influential discoveries are the confirmation of the structure of penicillin as previously surmised by Edward Abraham and Ernst Boris Chain; and mapping the structure of vitamin B12, for which in 1964 she became the third woman to win the Nobel Prize in Chemistry. Hodgkin also elucidated the structure of insulin in 1969 after 35 years of work. Hodgkin used the name "Dorothy Crowfoot" until twelve years after marrying Thomas Lionel Hodgkin, when she began using "Dorothy Crowfoot Hodgkin". Hodgkin is referred to as "Dorothy Hodgkin" by the Royal Society (when referring to its sponsorship of the Dorothy Hodgkin fellowship), and by Somerville College. The National Archives of the United Kingdom refer to her as "Dorothy Mary Crowfoot Hodgkin". The case of her Nobel prize is inscribed 'Crowfoot Hodgkin'.
== Evidence == While good to moderate scientific evidence exists for several of the included training principles – e.g. the inclusion of elastic recoil as well as a training of proprioceptive refinement – there is currently insufficient evidence for the claimed beneficial effects of a fascia oriented exercises program as such, consisting of a combination of the above described four training elements. Self-myofascial release using a foam roller or roller massager pre- and post-exercise has been observed to decrease soreness due to DOMS. Self-myofascial release appears to have no negative effect on performance.
== Treatment == Treatment should be directed towards the specific underlying cause of the vasculitis. If no underlying cause is found and the vasculitis is truly limited to the skin, then treatment is primarily supportive. Such treatment involves measures such as leg elevation, stockings, and topical steroids to relieve itching/burning. If the vasculitis does not self-resolve within 3–4 weeks, more aggressive treatment may be warranted. Oral colchicine or dapsone are often used for this purpose. If rapid control of symptoms is needed, a short course of high-dose oral steroids may be given. Immunosuppressive agents such as methotrexate and azathioprine may be used in truly refractory cases not responsive to colchicine or dapsone.
Sources: en.wikipedia.org
Fourteen isotopes of lawrencium are known, with mass number 251–262, 264, and 266; all are radioactive. Seven nuclear isomers are known. The longest-lived isotope, 266Lr, has a half-life of about ten hours and is one of the longest-lived superheavy isotopes known. However, shorter-lived isotopes are usually used in chemical experiments because 266Lr can only be produced as a final decay product of even heavier and harder-to-make elements: it was discovered in 2014 in the decay chain of 294Ts. 256Lr (half-life 27 seconds) was used in the first chemical studies on lawrencium: the longer-lived 260Lr (half-life 2.7 minutes) is usually used for this purpose. After 266Lr, the longest-lived isotopes are 264Lr (4.8+2.2−1.3 h), 262Lr (3.6 h), and 261Lr (44 min). All other known lawrencium isotopes have half-lives under 5 minutes, and the shortest-lived of them (251Lr) has a half-life of 24.4 milliseconds. The half-lives of lawrencium isotopes mostly increase smoothly from 251Lr to 266Lr, with a dip from 257Lr to 259Lr.
== Culture and history == Antidepressant discontinuation symptoms were first reported with imipramine, the first tricyclic antidepressant (TCA), in the late 1950s, and each new class of antidepressants has brought reports of similar conditions, including monoamine oxidase inhibitors (MAOIs), SSRIs, and SNRIs. As of 2001, at least 21 different antidepressants, covering all the major classes, were known to cause discontinuation syndromes. The problem has been poorly studied, and most of the literature has been case reports or small clinical studies; incidence is hard to determine and controversial. With the explosion of use and interest in SSRIs in the late 1980s and early 1990s, focused especially on Prozac, interest grew as well in discontinuation syndromes. Some of the symptoms emerged from discussion boards where people with depression discussed their experiences with the disease and their medications; "brain zaps" or "brain shivers" was one symptom that emerged via these websites. Heightened media attention and continuing public concerns led to the formation of an expert group on the safety of SSRIs in England to evaluate all the research available prior to 2004. The group determined that the incidence of discontinuation symptoms are between 5% and 49%, depending on the particular SSRI, the length of time on the medicine and abrupt versus gradual cessation. With the lack of a definition based on consensus criteria for the syndrome, a panel met in Phoenix, Arizona, in 1997 to form a draft definition, which other groups continued to refine.
== Teams == The FA Cup was a knockout competition with 124 teams taking part all trying to reach the final at Wembley on 3 June 2023. The competition consisted of the 92 teams from the Football League system (20 teams from the Premier League and the 72 in total from the EFL Championship, EFL League One and EFL League Two) plus the 32 surviving teams out of 640 teams from the National League System (all but eleven clubs from 5–9 and eleven replacements from tier 10 of the English football league system) that started the competition in the qualifying rounds. Qualification rounds were on a geographical basis and main competition rounds were drawn randomly usually either at the completion of the previous round or on the evening of the last televised game of a round being played depending on television broadcasting rights.
Sources: en.wikipedia.org
The Leidenfrost point signifies the onset of stable film boiling. It represents the point on the boiling curve where the heat flux is at the minimum and the surface is completely covered by a vapor blanket. Heat transfer from the surface to the liquid occurs by conduction and radiation through the vapour. In 1756, Leidenfrost observed that water droplets supported by the vapor film slowly evaporate as they move about on the hot surface. As the surface temperature is increased, radiation through the vapor film becomes more significant and the heat flux increases with increasing excess temperature. The minimum heat flux for a large horizontal plate can be derived from Zuber's equation,
=== Formulations === Metoprolol was synthesized and its activity discovered in 1969. The specific agent in on-market formulations of metoprolol is either metoprolol tartrate or metoprolol succinate, where tartrate is an immediate-release formulation and the succinate is an extended-release formulation (with 100 mg metoprolol tartrate corresponding to 95 mg metoprolol succinate). Metoprolol tartrate was first developed by Novartis and this dosage form received approval in the US in 1978. The extended-release salt, metoprolol succinate was developed by Astra Pharmaceuticals, and received a US patent in 1992.
==== 2023–24 UEFA Women's Nations League B ==== 23 September – Ireland 3–0 Northern Ireland. 26 September – Hungary 0–4 Ireland. 27 October – Ireland 5–1 Albania. 31 October – Albania 0–1 Ireland. 1 December – Ireland 1–0 Hungary. 5 December – Northern Ireland 1–6 Ireland.
== The Medical Sciences Club of South Australia == The Medical Sciences Club of South Australia, one of the oldest scientific clubs in Australia, was founded in Adelaide in 1920 as a means through which researchers in the sciences considered fundamental to medicine and medical practitioners interested in those aspects of medicine could regularly come together for their mutual benefit and for the advancement of biological and medical science. The club's inaugural meeting was held at the University of Adelaide on 16 April 1920. The fourteen medical men and scientists who attended the meeting were: Mr. Lionel Bull; Dr. Trent Champion de Crespigny; Dr. Raphael Cilento; Professor John Burton Cleland; Dr. Henry Fry; Dr. Frank Hone; Professor F. Wood Jones; Dr. Henry S. Newland; Dr. Robert Pulleine; Dr. William Ray; Professor Edward Rennie; Professor T. Brailsford Robertson; Dr. Malcolm Leslie Scott, M.B. B.S., M.R.C.S., F.R.C.S., M.Ch. (1882–1931); and Dr Harry Swift. The meeting appointed Dr Harry Swift as the club's temporary chairman, and Brailsford Robertson as its temporary secretary. Aside from its regular monthly meetings, the club was responsible for the on-going, quarterly publication of The Australian Journal of Experimental Biology and Medical Science from its first issue (March 1924) until its last issue (December 1986), after which it was re-named Immunology & Cell Biology.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.